Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
History
Vaxcyte was founded in 2018, combining the pioneering spirit of innovation, unyielding commitment to science, and drive to help prevent, control and manage life-threatening infectious diseases.
Mission
To develop and deliver vaccines, treatments and cures that benefit humankind worldwide.
Vision
Vaxcyte’s vision is to be a world leader in the prevention, control and management of life-threatening infectious diseases.
